This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Socinski, M. A. Search for Related Content PubMed PubMed Citation Articles by Socinski, M. A.

Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer

The Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina, USA

Correspondence: Mark A. Socinski, MD, MTOP, University of North Carolina, CB #7305, Chapel Hill, North Carolina 27599, USA. Telephone: 919-966-4431; Fax: 919-966-6735; e-mail: socinski{at}med.unc.edu

Paclitaxel was the first identified member of a new class of anticancer drugs known as the taxanes. This compound has significant single-agent activity against a number of solid tumors including nonsmall cell lung cancer (NSCLC). In the first-line setting, single-agent paclitaxel has been studied on a number of different schedules and dose levels. Initial studies were done on the 24-h infusion schedule with doses of 200-250 mg/m². Response rates were 21%-24%. Median survival ranged from six to nine months with one-year survival rates of 38%-42%. The major toxicity of this infusion schedule was myelosuppression, mainly neutropenia. Subsequent single-agent studies employed shorter infusion durations (three hours), with doses ranging from 175-225 mg/m². The cumulative experience of the 3-h infusion schedule shows an overall response rate of 28.5% with median survival of 6-11 months and a one-year survival of 37.5%. Similar results were obtained in the one study examining the 1-h infusion schedule with doses ranging from 135-200 mg/m². The major toxicities of the shorter infusion schedule include neutropenia, neuropathy, and myalgia/arthralgia syndrome. Weekly administration of paclitaxel also showed significant activity in advanced, metastatic NSCLC. Overall response rates have ranged from 30%-56% in the phase I/II setting with one-year survival rates of 42%-53%. A recently completed phase III trial comparing single-agent paclitaxel at 200 mg/m² over three hours every three weeks to best supportive care (BSC) in advanced or metastatic NSCLC has shown a survival advantage for the single-agent paclitaxel arm (median survival 6.8 months for paclitaxel versus 4.8 months for BSC, p = 0.045). An ongoing phase III trial is comparing single-agent paclitaxel to the combination of carboplatin and paclitaxel (CALGB 9730) in advanced, metastatic NSCLC. Paclitaxel has also been studied in the second-line setting. Infusion schedules have ranged from 1 h, 24 h and 96 h on an every-three-week schedule. Weekly paclitaxel has also been evaluated in the second-line setting. Although the overall experience is limited, response rates have ranged from 0%-38%. The overall role of single-agent paclitaxel in prolonging survival and improving quality of life remains uncertain in this setting.

The cumulative experience of single-agent paclitaxel in advanced, metastatic NSCLC suggests that it is a highly active cytotoxic agent in this setting. The consistent finding of a 35%-40% one-year survival rate is notable. The major toxicities include neutropenia, neuropathy, and myalgia/arthralgia syndrome. Given the overall activity and impact on survival along with an acceptable toxicity profile, single-agent paclitaxel warrants comparison to other active agents and combination regimens in advanced, metastatic NSCLC.

Key Words. Paclitaxel • NSCLC

This article has been cited by other articles:

				M. A. Socinski Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab Clin. Cancer Res., August 1, 2007; 13(15): 4597s - 4601s. [Abstract] [Full Text] [PDF]

				M. Matsumoto, M. Inoue, A. Hald, W. Xie, and H. Ueda Inhibition of Paclitaxel-Induced A-Fiber Hypersensitization by Gabapentin J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 735 - 740. [Abstract] [Full Text] [PDF]

				M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, and M. J. Hawkins Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Onc., August 1, 2006; 17(8): 1263 - 1268. [Abstract] [Full Text] [PDF]

				C.M.F. Kruijtzer, J.H.M. Schellens, J. Mezger, M.E. Scheulen, U. Keilholz, J.H. Beijnen, H. Rosing, R.A.A. Mathot, S. Marcus, H. van Tinteren, et al. Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2002; 20(23): 4508 - 4516. [Abstract] [Full Text] [PDF]

				C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]

				O. Juan, A. Albert, F. Ordono, R. Casany, V. Caranana, J. M. Campos, and V. Alberola Low-dose Weekly Paclitaxel as Second-line Treatment for Advanced Non-small Cell Lung Cancer: a Phase II Study Jpn. J. Clin. Oncol., November 1, 2002; 32(11): 449 - 454. [Abstract] [Full Text] [PDF]

				P. Fidias, J. G. Supko, R. Martins, A. Boral, R. Carey, M. Grossbard, G. Shapiro, P. Ostler, J. Lucca, B. E. Johnson, et al. A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3942 - 3949. [Abstract] [Full Text] [PDF]

				M. A. Socinski, A. B. Sandler, L. L. Miller, P. K. Locker, C. K. Hanover, G. L. Elfring, V. K. Israel, N. Pirotta, and R. B. Natale Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2001; 19(4): 1078 - 1087. [Abstract] [Full Text] [PDF]